Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

Universities are waiting cautiously as the agency's unilateral plan to cut billions of research support dollars has already ...

There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...